Medical Health & Life Science Research News

Research delivers insight into the Duchenne muscular dystrophy pipeline market review, H1 2018

Medical Market Research

The latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2018, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.

- Advertising -

Duchenne muscular dystrophy (DMD) is a genetic disorder that causes muscles to gradually weaken over time. Signs and symptoms of DMD include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.

Risk factors include gender and family history. Treatment includes steroid medication, respiratory therapy and surgery. 

- Advertising -

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy Pipeline Market Review, H1 2018, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Duchenne Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 17, 10, 47 and 12 respectively.

Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 9 and 1 molecules, respectively.

Get this Research Report at www.reportsnreports.com/contacts/d…aspx?name=1367683

Duchenne Muscular Dystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

For Details Inquire at www.reportsnreports.com/contacts/i…aspx?name=1367683

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
  • The pipeline guide reviews latest news related to pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders)

Table of Contents
Introduction
Duchenne Muscular Dystrophy - Overview
Duchenne Muscular Dystrophy - Therapeutics Development
Duchenne Muscular Dystrophy - Therapeutics Assessment
Duchenne Muscular Dystrophy - Companies Involved in Therapeutics Development
Duchenne Muscular Dystrophy - Drug Profiles
Duchenne Muscular Dystrophy - Dormant Projects
Duchenne Muscular Dystrophy - Discontinued Products
Duchenne Muscular Dystrophy - Product Development Milestones
Appendix

News From

ReportsnReports - Industry Trends & ForecastsReportsnReports
Category: Market Research Publishers and RetailersCompany about: ReportsnReports.com provides market research reports to industries, individuals and organizations with an objective of helping them in their decision-making process. Our library of 400,000+ industry & country research reports covers 5000+ micro markets.
This email address is being protected from spambots. You need JavaScript enabled to view it.